1Y Close · As of Aug 26, 2026
EuBiologics operates in the Pharmaceuticals sector.
Legal name: EuBiologics Co., Ltd.
In fiscal year 2023, EuBiologics (206650) reported revenue of 69.4 billion KRW, up 25.1% from 55.5 billion KRW a year earlier.
Operating profit was 7.7 billion KRW and net income was -15.4 billion KRW in the same year.
As of the Aug 26, 2026 close, the market capitalization was 330.8 billion KRW, with a P/B of 1.89.
These figures can be verified in the DART filing (receipt no. 20260317000832).
Financials
| Year | Rev | Op Inc | Net Inc |
|---|---|---|---|
| 2023 | 69.4B | 7.7B | -15.4B |
| 2022 | 55.5B | -3.8B | -3.4B |
| 2021 | 39.4B | -7.2B | -28.0B |
Recent Filings
Trust Termination Report
Share Retirement Decision
Material Event Report (Treasury Trust Termination)
Checks
No items require attention at this time.
Market Cap & Price: Market cap is above the delisting threshold.
Administrative Designation: No administrative designation criteria met.
Audit Opinion: Audit opinion: Unqualified (clean).
Convertible Bonds: No convertible bonds outstanding.
Capital Increase: No capital-increase filings in the last 180 days.
Treasury Stock: Treasury stock filings in the last 3 years: 1 cancellation(s).
Embezzlement & Litigation: No embezzlement or litigation filings in the last 180 days.
Major Shareholder Change: No major shareholder changes in the last 180 days.
Market Action: No market actions recorded in the last 180 days.
Recent Filings
| Date | Filing |
|---|---|
| 2026-08-24 | Trust Termination Report |
| 2026-08-21 | Share Retirement Decision |
| 2026-08-21 | Material Event Report (Treasury Trust Termination) |
| 2026-08-18 | Material Business Matters (Clinical Trial Approval Application) |
| 2026-08-13 | Semi-Annual Report (2026.06) |